Trastuzumab and Pertuzumab in HER2-Positive Metastatic Breast Cancer in West Africa: A Retrospective Cohort Study from Côte d’Ivoire Study HER2-Breast-CIV
Abstract
Background: Dual anti-HER2 blockade with trastuzumab plus pertuzumab combined with a taxane is the first-line treatment for metastatic HER2-positive breast cancer. However, little evidence is available on its efficacy and safety in sub-Saharan African populations. We aimed to report the effect of dual anti-HER2 blockade in Côte d’Ivoire on a cohort of patients followed up for HER2-positive metastatic breast cancer.
Methods: We conducted a retrospective analytical cohort study of female patients with HER2-positive metastatic breast cancer who were followed up in the public cancer management hospitals in Côte d’Ivoire (Treichville University Hospital Center and the National Center for Radiation Oncology) over a 2-year period from January 1, 2021, to December 31, 2022. The outcome of interest was progression-free survival, estimated by the Kaplan-Meier method. A univariable Cox regression model was used to test factors associated with progression-free survival. Variables with P < 0.10 were included in the multivariable model.
Results: We collected data on 30 patients. The median age was 47.2 years (interquartile range, 25 years). Common metastatic sites were the lung (63.3%), pleura (20.0%), liver (20.0%), bone (16.7%), and brain (6.7%). The most frequent adverse events were anemia (93.3%) and neutropenia (73.3%). The objective response rate was 60.0%. The median progression-free survival was 15.3 months. Median overall survival was not reached. Factors associated with better progression-free survival were the absence of brain metastasis (P = 0.003) and the administration of dual anti-HER2 blockade as first-line therapy (P = 0.005).
Conclusion: Dual anti-HER2 blockade showed therapeutic activity in terms of objective response, progression-free survival, and tolerability.
Full text article
References
Aka E, Horo A, Koffi A, Fanny M, Didi-Kouko C, Nda G, Abouna A, Kone M. Expérience africaine monocentrique de la prise en charge personnalisée des cancers du sein à Abidjan : défis et perspectives [Management of breast cancer in Abidjan: A single center experience]. Gynecol Obstet Fertil Senol. 2021 Sep; 49(9):684-690. doi:10.1016/j.gofs.2021.03.001.
Tai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release. 2010 Sep 15; 146(3):264-75. doi:10.1016/j.jconrel.2010.04.009.
Asanuma H, Torigoe T, Kamiguchi K, Hirohashi Y, Ohmura T, Hirata K, et al. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells. Cancer Res. 2005; 65:11018‑25. doi:10.1158/0008-5472.CAN-05-0491.
Arnold L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer. 2006; 94:259‑67. doi: 10.1038/sj.bjc.6602930.
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344:783‑92. doi:10.1056/NEJM200103153441101.
Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer. N Engl J Med. 2012 ;366:109‑19. doi:10.1056/NEJMoa1113216.
Sabatier R, Gonçalves A. Autorisation de mise sur le marché du pertuzumab (Perjeta®) dans les cancers du sein métastatiques HER2 positifs. Bull Cancer (Paris) 2014 ;101:765‑71. doi:10.1684/bdc.2014.1940.
Yesufe AA, Assefa M, Bekele A, Ergete W, Aynalem A, Wondemagegnehu T, et al. Adequacy of pathologic reports of invasive breast cancer from mastectomy specimens at Tikur Anbessa specialized hospital oncology center in Ethiopia. J Glob Oncol. 2018 ;1‑12. doi:10.1200/JGO.17.00198.
Gnangnon FHR, Seidou F, Laleye CM, Odidi FP, Flenon Nakou A, Tonato Bagnan JA, et al. Adequacy of histopathology request forms and pathological reports of breast cancer surgical specimens in Benin. Med Trop Sante Int. 2023;3:mtsi.v3i4.2023.348. doi: 10.48327/mtsi.v3i4.2023.348.
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, et al. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication. Ann Oncol Off J Eur Soc Med Oncol. 2021;32:1245‑55. doi: 10.1016/j.annonc.2021.06.024.
Joko-Fru WY, Griesel M, Mezger NCS, Hämmerl L, Seraphin TP, Feuchtner J, et al. Breast Cancer Diagnostics, Therapy, and Outcomes in Sub-Saharan Africa: A Population-Based Registry Study. J Natl Compr Canc Netw. 2021;20. doi: 10.6004/jnccn.2021.7011.
Witzel I, Müller V, Abenhardt W, Kaufmann M, Schoenegg W, Schneeweis A, et al. Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry. BMC Cancer. 2014 ;14:806. doi:10.1186/1471-2407-14-806.
Kleeberg UR, Fink M, Tessen H-W, Nennecke A, Hentschel S, Bartels S. Adjuvant therapy reduces the benefit of palliative treatment in disseminated breast cancer - own findings and review of the literature. Onkologie. 2013; 36:348‑56. doi: 10.1159/000351253.
Pieńkowski T, Zielinski CC. Trastuzumab treatment in patients with breast cancer and metastatic CNS disease. Ann Oncol. 2010 ;21:917‑24. doi: 10.1093/annonc/mdp353.
Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol. 2000 ;18 :2349‑51. doi: 10.1200/JCO.2000.18.11.2349.
Di Maio M, Bighin C, Schettini F, Ruelle T, Marandino L, Fabi A, et al. Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study. Breast Off J Eur Soc Mastology. 2023; 72:103583. doi: 10.1016/j.breast.2023.103583.
Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, Lin NU, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597–609. doi:10.1056/NEJMoa1914609.
Swain SM, Kim S-B, Cortés J, Ro J, Semiglazov V, Campone M, et al. Overall survival benefit with pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer in CLEOPATRA, a randomised Phase 3 study. Lancet Oncol. 2013;14:461‑71. doi: 10.1016/S1470-2045(13)70130-X.
Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020; 21:519‑30. doi: 10.1016/S1470-2045(19)30863-0.
Authors
Copyright (c) 2025 Archives of Breast Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright©. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License, which permits copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, except for commercial purposes.